Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.43 |
| ▸ | HRH1 | P35367 | 7/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GSTA1 | P08263 | 2/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540134 | 0.89 | HTR2A (0.41) | HTR2AHRH1HTR2CDRD2SLC6A2 | |
| SCHEMBL15541434 | 0.76 | HTR2A (0.45) | HTR2AHRH1HTR2CDRD2SLC6A2 | |
| SCHEMBL15541260 | 0.75 | PPARA (0.44) | HTR2AHRH1GSTA1GSTP1 | |
| SCHEMBL15541505 | 0.74 | HTR2A (0.40) | HTR2AHRH1HTR2C | |
| SCHEMBL15541243 | 0.73 | KDM4E (0.43) | HTR2ADRD2 | |
| SCHEMBL7156095 | 0.71 | HTR2A (0.57) | HTR2AHRH1HTR2CDRD2SLC6A2 | |
| SCHEMBL877438 | 0.68 | HTR2A (0.56) | HTR2A | |
| Hydroxyamine SCHEMBL11037119 | 0.67 | CD69 (0.44) | HTR2ADRD2 | |
| SCHEMBL3977109 | 0.67 | HTR2A (0.54) | HTR2A | |
| SCHEMBL6060761 | 0.67 | HTR2A (0.54) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150147273-A1 | RADIOLABELED ANALOG(S) OF COMPOUND 0118 AND USE THEREOF IN CONNECTION WITH PET AND/OR SPECT IMAGING TO DETERMINE WHETHER A PHARMACEUTICAL CONTAINING COMPOUND 0118 IS A CANDIDATE CANCER TREATMENT FOR A PATIENT | KONINKLIJKE PHILIPS N.V. (NL) | 2015-05-28 | — | — | US | disclosed |
| EP-2858681-A2 | RADIOLABELED ANALOG(S) OF COMPOUND 0118 AND USE THEREOF IN CONNECTION WITH PET AND/OR SPECT IMAGING TO DETERMINE WHETHER A PHARMACEUTICAL CONTAINING COMPOUND 0118 IS A CANDIDATE CANCER TREATMENT FOR A PATIENT | Koninklijke Philips N.V. (NL) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013186690-A2 | RADIOLABELED ANALOG(S) OF COMPOUND 0118 AND USE THEREOF IN CONNECTION WITH PET AND/OR SPECT IMAGING TO DETERMINE WHETHER A PHARMACEUTICAL CONTAINING COMPOUND 0118 IS A CANDIDATE CANCER TREATMENT FOR A PATIENT | KONINKLIJKE PHILIPS N.V. (NL) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150147273-A1 | RADIOLABELED ANALOG(S) OF COMPOUND 0118 AND USE THEREOF IN CONNECTION WITH PET AND/OR SPECT IMAGING TO DETERMINE WHETHER A PHARMACEUTICAL CONTAINING COMPOUND 0118 IS A CANDIDATE CANCER TREATMENT FOR A PATIENT | LGALS1, LGALS8, LGALS2 | HTR2A 3398/4885HRH1 2766/4885HTR2C 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.